Establishing growing body of preclinical data evaluating the DNase-based oncology platform across a number of high-value oncology indicationsOngoing progress towards first in human clinical study for ...
Company is advancing DNase-based oncology program towards clinical proof-of-concept studies in multiple indications FRAMINGHAM, MA / ACCESSWIRE / November 7, 2024 / Xenetic Biosciences, Inc.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...
At close: November 8 at 4:35 PM GMT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback